Sirona Biochem Retains Strategic Advisor to Commercialize Glycoproteins

VANCOUVER, BC--(Marketwired - November 03, 2015) - Sirona Biochem Corp. (TSX VENTURE: SBM) (FRANKFURT: ZSB) (XETRA: ZSB), (the "Company") is pleased to announce that it has retained Dr. Mason Ross as a strategic advisor to the Company. Mason's role will be primarily to provide strategic advice and an action plan for the Company's glycoprotein project, more specifically, revenue generating opportunities, commercial viability, risks and data gaps.

Mason has extensive experience in the pharmaceutical and biotech fields. He has held various medical and commercial responsibilities at Amgen, including leading the commercialization of their new products, and at GlaxoSmithKline leading medical affairs for their specialty care portfolio. Most recently, Mason was the Vice President of Medical Affairs at Nordion, where he focused on the development and commercialization of TheraSphere^®, which was sold to BTG for $200 million.

Mason earned his Honors Bachelor of Science in Physiology (1997), Doctor of Medicine (2001) and Master of Business Administration (2010) from the University of Western Ontario.

"I look forward to working closely with management on the glycoprotein project over the next few months," said Dr. Mason Ross. "I can't think of a company that is better positioned than Sirona to demonstrate how novel carbohydrate technology may result in a wide range of useful products. The potential for this technology may be enormous."

"We decided to bring Mason on board for his proven biotech/pharma successes and to support us in building a plan to commercialize our glycoproteins while we direct our immediate efforts towards closing a major transaction for our newest skin-lightener," said Dr. Howard Verrico, CEO of Sirona Biochem.

About Sirona Biochem

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information please visit www.sironabiochem.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.